In this task, you're given a paragraph and title from the research paper. Your task is to classify whether the given title is suitable or not for the research paper based on the given paragraph. Return "True" if title is proper according to paragraph else "False".

Paragraph: Rationale: Ex vivo, bronchial epithelial cells from people with asthma are more susceptible to rhinovirus infection caused by deficient induction of the antiviral protein, IFN-b. Exogenous IFN-b restores antiviral activity. Objectives: To compare the efficacy and safety of inhaled IFN-b with placebo administered to people with asthma after onset of cold symptoms to prevent or attenuate asthma symptoms caused by respiratory viruses. Methods: A total of 147 people with asthma on inhaled corticosteroids (British Thoracic Society Steps 2-5), with a history of virus-associated exacerbations, were randomized to 14-day treatment with inhaled IFN-b (n = 72) or placebo (n = 75) within 24 hours of developing cold symptoms and were assessed clinically, with relevant samples collected to assess virus infection and antiviral responses. Measurements and Main Results: A total of 91% of randomized patients developed a defined cold. In this modified intention-to-treat population, asthma symptoms did not get clinically significantly worse (mean change in six-item Asthma Control Questionnaire ,0.5) and IFN-b treatment had no significant effect on this primary endpoint, although it enhanced morning peak expiratory flow recovery (P = 0.033), reduced the need for additional treatment, and boosted innate immunity as assessed by blood and sputum biomarkers. In an exploratory analysis of the subset of more difficult-to-treat, Step 4-5 people with asthma (n = 27 IFN-b; n = 31 placebo), Asthma Control Questionnaire-6 increased significantly on placebo; this was prevented by IFN-b (P = 0.004). Conclusions: Although the trial did not meet its primary endpoint, it suggests that inhaled IFN-b is a potential treatment for virus-induced deteriorations of asthma in difficult-to-treat people with asthma and supports the need for further, adequately powered, trials in this population. Clinical trial registered with www.clinicaltrials.gov (NCT 01126177). 
 Title: The Effect of Inhaled IFN-b on Worsening of Asthma Symptoms Caused by Viral Infections A Randomized Trial
True

Paragraph: Worldwide community-acquired pneumonia (CAP) is one of the most frequent infectious diseases and a leading cause of death. Several studies have shown that a pathogen could be identified only in 50 to 60% of all patients, although in children < 6 month infectious agents can be detected in about 90%. Viral infections are most frequent in children < 2 years (80%), whereas bacterial infections increase with age. RSV, influenzaviruses, rhinoviruses, parainfluenzaviruses and adenoviruses are the most common viruses associated with CAP in children. Among adenoviruses a predominance of adenovirus 7 has been reported in several countries with emergence of highly pathogenic variants with significant lethality in young children. Many childhood respiratory infections are caused by more than one pathogen and up to 30% mixed viral / bacterial infections can be observed. CAP in immunocompetent adults is rare, whereas persons with underlaying diseases have an increased incidence of CAP. In the elderly, RSV, influenzaviruses, parainfluenzaviruses and less frequent adenoviruses are predominant viruses causing pneumonia. Less frequently associated with CAP are the newly discovered human metapneumovirus and the coronaviruses NL63 and HKU1. Hantaviruses, involved in the hantavirus pulmonary syndrome, belong to the emerging pathogens to date in North, Middle and South America. For optimum diagnosis the whole spectrum of potential respiratory viral agents should be included and multiple diagnostic techniques have to be used. In view of the high relevance of influenzavirus for CAP influenza vaccination is highly advisable for prevention of CAP, especially in high-risk groups. 
 Title: Community-Acquired Pneumonia Viral pathogens and epidemiology, detection, therapy and resistance
True

Paragraph: Dengue virus causes dengue fever, a debilitating disease with an increasing incidence in many tropical and subtropical territories. So far, there are no effective antivirals licensed to treat this virus. Here we describe the synthesis and antiviral activity evaluation of two compounds based on the quinoline scaffold, which has shown potential for the development of molecules with various biological activities. Two of the tested compounds showed dose-dependent inhibition of dengue virus serotype 2 in the low and sub micromolar range. The compounds 1 and 2 were also able to impair the accumulation of the viral envelope glycoprotein in infected cells, while showing no sign of direct virucidal activity and acting possibly through a mechanism involving the early stages of the infection. The results are congruent with previously reported data showing the potential of quinoline derivatives as a promising scaffold for the development of new antivirals against this important virus. Molecules 2018, 23, 672 2 of 11 antivirals might be very useful in the case of severe dengue, as high viremia has been shown to correlate with severity [7]. Quinolines are heterocyclic molecules composed of fused benzene and pyridine rings. The quinolines and their derivatives have shown a wide range of biological activities, including antiproliferative [8], antiviral [9], antibacterial [10], antifungal [11], anti-inflammatory [12], and antiparasitic [13]. Members of the quinoline family, such as chloroquine and hydroxychloroquine, have shown antiviral activity against several viruses, such as coronaviruses [9], human immunodeficiency virus [14], and respiratory syncytial virus [15]. Concerning Flavivirus, quinoline derivatives have proved active against the Hepatitis C virus [16], West Nile virus [17,18], Japanese Encephalitis virus [19], Zika virus [20], and dengue virus [21]. Since the quinoline scaffold has shown high potential for the development of new molecules with antiviral activity, we decided to synthesize and test several quinoline derivatives and related compounds. Here we describe the synthesis, screening, and characterization of antiviral activity of two novel quinoline derivatives against the dengue virus serotype 2 (DENV2) in vitro. Quinoline compounds have shown potential as new scaffolds for the development of drugs with pharmacological activities against various human pathogens, including viruses. In order to investigate the possible antiviral potential of several new quinoline derivatives, we synthesized a number of derivative compounds and tested their ability to impair infection by DENV2 in a medium-throughput assay based on cellular ATP detection. Synthetically, substituted quinolines can be accessed from quinoline or quinoline N-oxide precursors. The N-oxides are typically prepared by N-oxidation of quinolines [22] . Several methods have recently been developed to prepare substituted quinolines from the unsubstituted precursors [23, 24] . We found that a modification of our recently developed N,N,N ,N -tetramethylethylenediamine (TMEDA)-catalyzed synthesis of 2-substituted quinolines [25] provided optimal yields and purity of quinolines 4 and 5 from 8-hydroxyquinoline N-oxide (3), although the copper-catalyzed reaction of Grignard reagents [26] gave similar results (Scheme 1). Using the TMEDA-catalyzed reaction, 2-alkylated quinolines 4 and 5 were isolated in 54 and 79% yields, respectively. Subsequent chlorination with N-chlorosuccinimide (NCS) under acidic conditions afforded the desired quinolines 1 and 2 in 78 and 80% yields, respectively Scheme 1 and Supplementary Materials). The final purity of both compounds 1 and 2 was verified to be higher than 97%. Molecules 2018, 23, x FOR PEER REVIEW 2 of 11 
 Title: molecules Antiviral Activity of Novel Quinoline Derivatives against Dengue Virus Serotype 2

True